Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, we show that blockade of IL-12p40 in the early phase of aneurysm development suppresses macrophage expansion, inflammatory cytokine and MMP-9 production and mitigates AAA development.
|
31320700 |
2019 |
Aortic Aneurysm, Abdominal
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to investigate the effect of functional polymorphisms in promoters of the MMP-2 (-1306 C > T), MMP-3 (-1171 5A > 6A), MMP-9 (-1562 C > T), MMP-12 (-82 A > G), TIMP-1 (-372 C > T), and PAI-1 (-675 4G > 5G and -847 A > G) genes on the growth rate of small abdominal aortic aneurysms.
|
17182940 |
2006 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
CLG4B, which encodes the 92-kDa form of type IV collagenase, is a candidate gene for AAA.
|
7762981 |
1995 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MSCs with stemness properties are niched in human AAA tissues and display a dysregulation of functional activities; that is, upregulation of MMP-9 and ineffective immunomodulatory capacity, which are crucial in the AAA progression; the possibility to modulate the increased MMP-9 expression by healthy MSCs and IL-10 suggests that novel therapeutic strategies are possible for slowing down AAA progression.
|
25854712 |
2015 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
B-cell-deficient muMT mice showed suppression of AAA development that was associated with reduced activation of Syk and less expression of matrix metalloproteinase-9.
|
29545260 |
2018 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, NGAL in complex with activated MMP-9 is present in AAA wall and thrombus.
|
17721627 |
2007 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Plasma protein levels were significantly elevated for osteopontin, MMP-2, and MMP-9 in the samples of ascending and abdominal aortic aneurysm group compared with controls.
|
22571802 |
2013 |
Aortic Aneurysm, Abdominal
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MMP9 rs2234681 microsatellite was the only genetic determinant of TE/A in AAA patients (P = .003), followed by hypercholesterolemia and antiplatelet use.
|
29291905 |
2018 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
There was a significant increase in the level of MMP-9 mRNA in AAA specimens (occlusive, 16.8 +/- 3, n = 3; donor, 5.7 +/- 1.2, n = 6; AAA, 56.7 +/- 11, n = 15, p = 0.0069).
|
9588507 |
1998 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
In in vivo experiments, 800 mg/kg GSP could significantly reduce the incidence of AAA, the dilatation of aorta and elastin degradation in media, and dramatically decrease macrophage infiltration and activation and expression of matrix metalloproteinase (MMP) -2 and MMP-9 in the aorta, compared to the AAA model group.
|
28839206 |
2017 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
MMP-9 deficiency augmented AngII-induced AAA.
|
28420827 |
2017 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast to plasma MMP-9, soluble glycoprotein V (sGPV) and plasmin-antiplasmin complex levels, plasma TIMP-3 levels were not correlated to AAA size but interestingly correlated to sGPV, a platelet activation marker.
|
20513153 |
2010 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In a mouse CaCl(2)-induced AAA model, the expression of HMGB1 was increased compared with that in sham, and was positively correlated with matrix metalloproteinase (MMP)-2 and MMP-9 activity.
|
22365948 |
2012 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gelatin zymography showed that quercetin eliminated matrix metalloproteinase (MMP)‑2 and MMP‑9 activation during AAA formation.
|
24337353 |
2014 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
LHGDN |
Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm.
|
17964292 |
2008 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
When Angptl2-deficient mice were used in the mouse model, they showed decreased AAA development compared with wild-type mice, as evidenced by reduction in aneurysmal size, less severe destruction of vessel structure, and lower expression of proinflammatory cytokines and matrix metalloproteinase-9.
|
22556334 |
2012 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
We therefore found no evidence that MMP-9 is a marker of susceptibility for AAA.
|
17223007 |
2007 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ex vivo experiments showed that mRNA expressions of TNF-α, MMP-2, and MMP-9 in the cultured AAA tissue were decreased by exogenous TG2, whereas were increased by cystamine.
|
20615646 |
2010 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm.
|
17964826 |
2008 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
AAA SMCs demonstrated twofold greater expression of MMP-2 messenger (m)RNA (P < .05) and 7.3-fold greater MMP-9 expression (P < .01) than NAA-SMCs.
|
24080131 |
2014 |
Aortic Aneurysm, Abdominal
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We also assessed the potential association between 2 functional single nucleotide polymorphisms in the genes MMP9 (-1561C/T; rs3918242) and MMP13 (-77A/G; rs2252070), and the presence of large AAAs.
|
29739236 |
2019 |
Aortic Aneurysm, Abdominal
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analyses identified MMP-9 p-2502 single nucleotide polymorphism (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.31-0.94; P = .029) as a significant confound discriminating between control vs slow-growth AAA, MMP-9 D165N (OR, 0.49; 95% CI, 0.26-0.95; P = .035) and LRP1 (OR, 4.99; 95% CI, 1.13-22.1; P = .034) between control vs aggressive-growth AAAs, and methyltetrahydrofolate reductase (OR, 2.99; 95% CI, 1.01-8.86; P = .048), MMP-9 p-2502 (OR, 2.19; 95% CI, 1.05-4.58; P = .037), and LRP1 (OR, 4.96; 95% CI, 1.03-23.9; P = .046) as the statistically significant confounds distinguishing slow-growth AAAs vs aggressive-growth AAAs.
|
24801553 |
2014 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our previous studies have demonstrated that macrophages are the major source of matrix metalloproteinase-9, which is required for aneurysmal degeneration in the murine AAA model.
|
14764734 |
2004 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
In a comparison of ruptured AAA biopsies, MMP-8 and -9 levels were significantly elevated in the 12 rupture site biopsies compared with their 12 paired anterior wall biopsies, whereas other MMPs and TIMPs showed no difference (MMP-8, P<0.001; MMP-9, P=0.01).
|
16432074 |
2006 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MMP3, MMP9, and PAI-1 are present at increased levels in abdominal aortic aneurysms (AAAs).
|
10558909 |
1999 |